Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

By R. Brentjens, J. Latouche, E. Santos, F. Martí, Michael C. Gong, Clay E. Lyddane, P. King, S. Larson, M. Weiss, I. Rivière and 1 more. Nature Medicine, 2003

669 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/7b006b158003e0afef35236c0ca5c40c47ab231b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. N. Restifo
2. Dimiter S. Dimitrov
3. S. Finkelstein
4. Yiping Yang
5. W. Leonard
6. Michel Sadelain
7. S. Rosenberg

In Oncology

1. S. Finkelstein
2. N. Restifo
3. Yiping Yang
4. W. Leonard
5. Michel Sadelain
6. S. Rosenberg
7. James J. Collins
8. Wilson W. Wong

Citations in the corpus

• Cancer immunotherapy: harnessing the immune system to battle cancer. (2015, background): “Later, it was shown that CD19 CAR-transduced human peripheral blood T lymphocytes could eradicate lymphoma and leukemia in immune-deficient mice (24).”
• Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. (2016, background): “Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.”
• Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells (2015, positive): “…potential of peripheral blood T cells transduced with these CARs, we devised a T cell ‘‘stress test’’ in which T cell doses are purposefully lowered to levels where CAR therapy begins to fail, based on the previously described NALM6 pre-B ALL model (Brentjens et al., 2003; Brentjens et al., 2007).”